Caris Life Sciences (CAI) Capital Expenditures (2024 - 2026)
Caris Life Sciences' (CAI) quarterly Capital Expenditures came in at -$153000.0 in Q1 2026, down 325.0% year-on-year from $68000.0 in Q1 2025, and up 98.64% quarter-over-quarter from -$11.2 million in Q4 2025.
Caris Life Sciences (CAI) Capital Expenditures (2024 - 2026) Analysis & Trends
Caris Life Sciences' Capital Expenditures history runs 3 years deep, the most recent figure standing at -$153000.0 for Q1 2026.
- On a quarterly basis, Capital Expenditures fell 325.0% year-over-year to -$153000.0 in Q1 2026; TTM through Mar 2026 was -$165000.0, a N/A change from a year earlier, with the FY2025 full-year figure at -$48000.0, down 100.57% from the prior year.
- Capital Expenditures rose to -$153000.0 in Q1 2026 per CAI's latest filing, from -$11.2 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $8.3 million in Q4 2024 and bottomed at -$11.2 million in Q4 2025.
- The 3-year median for Capital Expenditures is -$36000.0 (2025), against an average of $559571.4.
- Across the five-year window, Capital Expenditures soared 270.23% in 2025 and tumbled 325.0% in 2026, its largest moves.
- Year by year, Capital Expenditures stood at $8.3 million in 2024, then plunged by 235.38% to -$11.2 million in 2025, then surged by 98.64% to -$153000.0 in 2026.
- Per Business Quant, the three latest CAI Capital Expenditures figures stand at -$153000.0 (Q1 2026), -$11.2 million (Q4 2025), and $7.1 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Caris Life Sciences | 4.42 Bn | 3.60 Bn | 214.23 Mn | -153,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -153,000.00 |
| Mar 31, 2026 | -153,000.00 |
| Dec 31, 2025 | -11.22 Mn |
| Dec 31, 2025 | -11.22 Mn |
| Sep 30, 2025 | 7.10 Mn |
| Sep 30, 2025 | 7.10 Mn |
| Jun 30, 2025 | 4.11 Mn |
| Jun 30, 2025 | 4.11 Mn |
| Mar 31, 2025 | -36,000.00 |
| Mar 31, 2025 | -36,000.00 |
| Dec 31, 2024 | 8.29 Mn |
| Dec 31, 2024 | 8.29 Mn |
| Sep 30, 2024 | -4.17 Mn |
| Sep 30, 2024 | -4.17 Mn |